What is Positrigo?
Positrigo is a Swiss MedTech company at the forefront of functional brain imaging. Their proprietary ultra-compact Positron Emission Tomography (PET) system, NeuroLF®, aims to democratize access to advanced brain diagnostics globally. The company's mission is to provide affordable and accessible solutions for the early detection and management of critical neurodegenerative disorders, including Alzheimer's disease, epilepsy, Parkinson’s disease, and brain tumors, thereby addressing a significant unmet medical need in neurological healthcare.
How much funding has Positrigo raised?
Positrigo has raised a total of $8.6M across 1 funding round:
Other Financing Round
$8.6M
Other Financing Round (2025): $8.6M with participation from HealthCap companies
Key Investors in Positrigo
HealthCap companies
HealthCap is a venture capital firm specializing in global life sciences investments, with a focus on diseases with high unmet medical needs and transformative therapies.
What's next for Positrigo?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Positrigo for accelerated growth and market penetration. This capital infusion is expected to fuel further development of their NeuroLF® system, expand manufacturing capabilities, and support broader clinical adoption. The company's focus on making advanced brain imaging accessible suggests a strategic push to capture a significant share of the global diagnostic market, potentially transforming patient care pathways for neurological conditions.
See full Positrigo company page
